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ABSTRACT
The hypothesis that functionally selective G protein–coupled
receptor (GPCR) agonists may have enhanced therapeutic
benefits has revitalized interest for many GPCR targets. In
particular, although k-opioid receptor (KOR) agonists are
analgesic with a low risk of dependence and abuse, their use
is limited by a propensity to induce sedation, motor incoordi-
nation, hallucinations, and dysphoria-like states. Several labo-
ratories have produced a body of work suggesting that G
protein–biased KOR agonists might be analgesic with fewer
side effects. Although that has been an intriguing hypothesis,
suitable KOR-selective and G protein–biased agonists have
not been available to test this idea. Here we provide data using
a G protein–biased agonist, RB-64 (22-thiocyanatosalvinorin A),
which suggests that KOR-mediated G protein signaling induces
analgesia and aversion, whereas b-arrestin-2 signaling may be
associated with motor incoordination. Additionally, unlike un-
biased KOR agonists, the G protein–biased ligand RB-64 does
not induce sedation and does not have anhedonia-like actions,
suggesting that a mechanism other than G protein signaling
mediates these effects. Our findings provide the first evidence
for a highly selective and G protein–biased tool compound for
which many, but not all, of the negative side effects of KOR
agonists can be minimized by creating G protein–biased KOR
agonists.
Introduction
The term functional selectivity or biased agonism describes
the ability of a G protein–coupled receptor (GPCR) ligand to
selectively activate a subset of signaling cascades at a partic-
ular GPCR, as opposed to the activation of all downstream
signaling cascades (e.g., G proteins, arrestins, and/or kinases).
Over the past few years, the phenomenon of functional
selectively has been increasingly explored, providing a novel
potential for GPCR-targeted therapies with improved safety
and fewer side effects (Urban et al., 2007; Allen and Roth,
2011). Currently, the potential of functionally selective drugs
as biased agonists for a wide range of targets and disease
states is being investigated. Thus, for instance, 1) angiotensin
II receptor arrestin–biased agonists are being investigated for
treating acute heart failure; 2) m-opioid receptor G protein
biased agonists have been proposed as novel analgesics; 3)
d-opioid receptor G protein–biased agonists are being consid-
ered for Parkinson disease, pain, and depression; and 4) the
dopamine D2 arrestin–biased agonists are being evaluated for
treating schizophrenia and related disorders (Allen et al.,
2011; Pradhan et al., 2011; Whalen et al., 2011; DeWire et al.,
2013; Monasky et al., 2013). Significantly, a wealth of data
implies that G protein–biased KOR ligands might represent
novel analgesics with lower addiction liability and fewer side
effects (Bruchas et al., 2007; Tao et al., 2008; Ranganathan
et al., 2012).
Although k-opioid receptor (KOR) agonists have long been
recognized to be analgesic with low abuse potential, their use
can be associated with severe side effects, including dyspho-
ria, anhedonia, and hallucinations (Pfeiffer et al., 1986;
Ranganathan et al., 2012; Tejeda et al., 2013). KOR activation
induces p38 mitogen-activated protein kinase (MAPK) acti-
vation in vivo, therebymediatingKOR-induced aversion inmice,
but not analgesia (Bruchas et al., 2007). It has been hypothe-
sized that p38 activation is mediated by b-arrestin-2 signaling
(Bruchas and Chavkin, 2010), suggesting a therapeutic poten-
tial for G protein–biased KOR ligands as analgesics without
dysphoric side effects. Until now, the only G protein–biased
KOR ligand identified, 69-GNTI (69-guanidinonaltrindole),
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was not suitable for in vivo study because it does not cross the
blood-brain barrier (Rives et al., 2012). Because of the lack of
suitable tool compounds, however, this hypothesis has not
been directly tested in vivo.
We recently reported that the centrally active salvinorin A
(sal A) derivative, RB-64 (22-thiocyanatosalvinorin A; Yan
et al., 2009), represents a G protein–biased KOR agonist
(White et al., 2014) and is a potential tool-like compound
suitable for interrogating the role of G protein signaling in
mediating various behavioral responses to KOR activation.
Using RB-64 in both wild-type (WT) and b-arrestin-2 KO
mice, we provide evidence in favor of the hypothesis that
KOR-mediated G protein signaling induces analgesic-like
effects and aversion, whereas KOR-mediated b-arrestin-2
signaling induces motor incoordination. Additionally, the G
protein–biased ligand RB-64 had no effect on motor coordi-
nation, sedation, or anhedonia, suggesting that these behav-
iors are not mediated by G protein signaling but instead,
perhaps, by b-arrestin-2 signaling. Based on these results, our
data support the hypothesis that G protein–biased KOR
agonists might represent novel analgesics with reduced abuse
potential and fewer deleterious side effects compared with
unbiased agonists.
Materials and Methods
In Vitro Functional Analysis of U69593, Sal A, and RB-64
ForU69593 [(1)-(5a,7a,8b)-N-methyl-N-[7-(1-pyrrolidinyl)-1-oxaspiro
[4.5]dec-8-yl]-benzeneacetamide], sal A, and RB-64, G protein activation
was measured using a previously described split-luciferase based cAMP
biosensor (Glowsensor 22F; Promega, Madison, WI) (Besnard et al.,
2012;White et al., 2014), whereas arrestinmobilizationwasmeasured
by Tango assay exactly as previously described (White et al., 2014),
with the exception that the mouse KOR was used instead of human
KOR. Bias calculations were performed as previously described (White
et al., 2014) (Fig. 1).
In Vitro Internalization Analysis
For these studies, FLAG-tagged hKOR was transiently transfected
into human embryonic kidney (HEK) cells, and the day after trans-
fection cells were plated onto polylysine-coated glass coverslips as
described previously (Bhatnagar et al., 2001). After 24 hours, cells
were exposed to 200 nM test compound for 0, 15, and 30 minutes and
then prepared for anti-FLAG immunofluorescence confocal micros-
copy done essentially as previously described (Bhatnagar et al., 2001).
Animal Subjects
C57BL/6J mice and knockout (KO) mice were acquired from The
Jackson Laboratory (Bar Harbor, ME), and b-arrestin-2 KO mice on
a C57BL/6J background were donated by the laboratory of Robert
Lefkowitz (Duke University, Durham, NC). Behavioral studies were
conducted at the University of North Carolina following the National
Institutes of Health’s guidelines for care and use of animals and with
approved mouse protocols from the institutional animal care and use
committees. An equal number of male and female subjects were age-
matched: 2- to 8-month-old mice weighing between 22 and 35 g;
genotypes were determined by polymerase chain reaction analysis of
tail-tip digestions. WT and b-arrestin-2 KO mice from b-arrestin-2
KO heterozygous parents (C57BL/6J background) were used for all
behavioral experiments. All mice were given access to food and water
ad libitum.
Drugs
Sal A was acquired from Apple Farms (Asheville, NC), and RB-64
was synthesized as previously reported (Yan et al., 2009). Finally,
U69593 was acquired from Sigma-Aldrich (St. Louis, MO). All drugs
were administered subcutaneously using 10% Tween-80 as vehicle,
unless otherwise stated. A dose of 3 mg/kg RB-64 was chosen for most
experiments because that was the lowest dose found to induce
analgesia-like effects.
Hotplate Assay
Analgesia-like responses weremeasured using a hotplate analgesia
meter with dimensions of 29.2  26.7 cm; mice were restricted to
a cylinder 8.9 cm in diameter and 15.2 cm high (IITC Life Sciences,
Woodland Hills, CA). Response was measured by recording the
latency to lick, flutter, or splay hindpaw(s) or an attempt to jump out
of the apparatus at 55°C, with a maximum cutoff time of 30 seconds.
Once a response was observed or the cutoff time had elapsed, the
subject was immediately removed from the hotplate and placed back
in its home cage (Balter and Dykstra, 2013). The animals were
acclimated to the hotplate, while cool, and a baseline analgesic
response time was acquired several hours before drug treatment and
testing. The analgesia-like effect was measured 10, 20, and 30
minutes after treatment administration. Animals that did not display
hindpaw lick, splay, or flutter were removed from the trial. Addi-
tionally, animals that attempted to jump out of the plate or urinated
on the hotplate were removed from the trial. For the vehicle-treated
group, 3 of the 15 WT animals were removed and 2 of the 11
b-arrestin-2 KO mice were removed. In the sal A–treated group, none
of 11 WT mice was removed and 5 of 21 b-arrestin-2 KO mice were
removed. In the U69593-treated group, 2 of 10WTmice were removed
and 4 of 14b-arrestin-2 KOwere removed. Finally, in theRB-64–treated
group, 1 of 10 mice was removed for bothWT and b-arrestin-2 KOmice.
Conditioned Place Aversion
The conditioned place aversion (CPA) protocol was modified from
Medvedev et al. (2005).
Apparatus. Drug-naïve mice were used for each treatment condi-
tion. A three-compartment place-preference chamber was used under
standardized environmental conditions using an AccuScan activity
monitor system (AccuScan Instruments, Columbus, OH). The location
of the subject was detected by photobeam strips, and the time spent in
each compartment was recorded. The experiments were conducted in
a room used only for animal behavior studies, and no other activity
in the room occurred during testing. The three compartments of the
chamber were separated by sliding doors, and the center compart-
ment was 40 cm long, 30 cm deep, and 5 cm wide with white walls and
plastic floor. The two larger compartments used during training were
40 cm long, 30 cm deep, and 17.5 cm wide. One compartment had
white and black vertical stripes with brown, perforated paper strips
on the flooring, and the other conditioning chamber had white and
black vertical stripes with Diamond Dry bedding (Harlan Laborato-
ries, Indianapolis IN) on the floor.
Pretest (Days 1–3). During this phase, mice were placed in the
center compartment and the doors were opened, so both test chambers
were accessible. The location of the mice was monitored for 15 minutes
during 3 days of pretest training. Mice were not considered suitable
for testing if they met the following criteria during the pretest: they
spent more than 25% of the time in the center compartment, they
spent less than 25% of the time in one of the conditioning compart-
ments, and/or they spent more time in the center compartment than
in one of the conditioning compartments (Medvedev et al., 2005).
Conditioning Phase (Days 4–9). Vehicle treatments were
performed on days 4, 6, and 8 and were restricted to the test chamber
that the particularmouse spent the least amount of time in during the
pretest phase. Drug treatments were conducted on days 5, 7, and 9
and were restricted to the test chamber where the particular mouse
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spent more time during the pretest. The vehicle control mice received
vehicle in both compartments during conditioning. Fifteen minutes
after drug treatment, mice were placed in the conditioning chamber
for an additional 15 minutes.
Test Phase (Day 11). After a 1-day drug washout period, mice
were placed in the center chamber and the doors were opened to allow
access to all rooms. No drug or vehicle was given on this day, and the
location of the mouse was measured for 15 minutes. Data were pooled
over the 15-minute testing phase for each mouse, and the CPA results
were analyzed for each mouse. The results were recorded as the
difference in time spent in the drug-paired compartment on the test
day versus pretest day.
Rotarod Performance
Balance and motor coordination were measured on an accelerating
rotarod after drug treatment (Ugo-Basile, Stoelting Co., Wood Dale,
IL) as previously reported (Huang et al., 2013). Briefly, the rod
initially rotated at 3 rpm, gradually increasing to a maximum of
30 rpm over a 5-minute period, which was also themaximum length of
the trial. Two days before the experiment, mice were trained on the
apparatus in two or three trials, with a 1-minute break between trials.
The latency to fall off the rod was measured by the rotarod timer.
Additionally, testing was stopped for mice that rotated off the top of
the rod. On testing days, each mouse first completed a drug-free trial
to determine baseline performance before administration of drug.
Rotarod performance was assessed 10, 20, and 30 minutes after drug
administration.
Novelty-Induced Locomotion
Mouse locomotion was measured in photocell-based activity
chambers under standardized environmental conditions using an
AccuScan activity monitoring system (AccuScan Instruments) con-
sisting of a 41  41  30-cm chamber with beam sensors as described
earlier (Farrell et al., 2013). Distance traveled consists of horizontal
movement throughout the entire chamber, and data were collected in
5-minute bins. Mice were given drug or vehicle treatments 15minutes
before being placed in the chamber, and locomotion was recorded for 1
hour. Mice were not habituated to chambers before assay.
Intracranial Self-Stimulation
Intracranial self-stimulation (ICSS) is an operant behavioral
method in which mice respond for rewarding electrical stimulation
of the medial forebrain bundle at the level of the lateral hypothala-
mus. All ICSS methods were done as previously described (Robinson
et al., 2012), using the curve-shift method of ICSS (Carlezon and
Chartoff, 2007). The maximum response rate (MAX) and the lowest
frequency that sustained responding brain stimulation reward (BSR
threshold, u0) were compared before and after drug administration.
Statistics
The data are presented as means and S.E.M. The hotplate, CPA,
rotarod, and novelty-induced locomotion studies were analyzed by
GraphPad Prism statistical software (GraphPad Software, La Jolla,
CA), whereas the ICSS studies were analyzed by SigmaPlot (Systat
Software Inc., San Jose, CA). The hotplate data were assessed using
two-way repeated measures (RM) analysis of variance (ANOVA) for
within-subject effect of time, between-subject effect of treatment, and
interaction between time and treatment (Fig. 2). The effect of KOR on
results was determined by a one-way ANOVA of the results fromKOR
KO mice compared with WT mice (Fig. 2D). Additionally, the effect of
genotype on baseline performance was measured by one-way ANOVA
(Fig. 2E). Furthermore, we used a two-tailed t test to determine
whether the analgesia-like response induced by 3 versus 10 mg/kg of
sal A or RB-64 produced a more pronounced effect (Fig. 2F). Results
are plotted as the percent of baseline for each mouse. The CPA data
were first assessed by a Bartlett test for equal variances to determine
whether the variances differ significantly, followed by a one-way
ANOVA (Fig. 3A). A two-tailed t test was performed with the drug
treatments that used a dimethylsulfoxide or 10% Tween-80 vehicle to
determine potential ceiling effects of the 10% Tween-80 vehicle on
1 mg/kg U69593 and 3 mg/kg RB64 (Fig. 3B)
Rotarod data were assessed by a two-way RM ANOVA for each
treatment condition. The within-subject effect of time, the between-
subject effect of genotype, and the effect of time on genotype were
reported (Fig. 4, A–C). A one-way ANOVA was used to analyze any
difference between baseline performances for each genotype (Fig. 4E).
Results are plotted as the percent of baseline performance for each
mouse. Novelty induced locomotion data were assessed by a two-way
RM ANOVA to determine the effect of genotype on locomotion (Fig. 5,
A–D). To determine the effect of treatment on the total distance
traveled within the first 30 minutes of the assay, a one-way ANOVA
was performed (Fig. 5E).
ICSS data were assessed by a two-way RM ANOVA to compare the
effects of drug and dose (Fig. 6). The lowest frequency that sustained
responding (BSR threshold) andMAX values were represented as the
percent of the predrug baseline for each mouse. A two-way RMANOVA
was performed to assess the effects of treatments on the average rate-
frequency curves. For all data sets assessed with two-way RM ANOVA
and one-way ANOVA, when significant (P, 0.05), all post-hoc analyses
were by Bonferroni corrected pairwise comparisons. To satisfy
assumptions for parametric analysis using a one-way ANOVA, data
were evaluated for equal variances using the Bartlett test.
Results
RB-64 Is an Extremely G Protein–Biased Ligand at
the Mouse KOR. RB-64 was originally identified as a G
protein–biased ligand from a screen using the human KOR
(White et al., 2014). Because prior studies have indicated that
mouse and human KOR may differ substantially with regard
to patterns of functional selectivity (Schattauer et al., 2012), it
was essential to evaluate the degree of bias for RB-64 at the
mouse KOR before in vivo studies. In an in vitro assay system,
we showed that RB-64 is nearly inactive at the arrestin
pathway and represents an exceptionally G protein–biased
agonist at the mouse KOR (bias factor 5 96) (Fig. 1; Table 1).
Importantly, U69593 is unbiased (bias factor 5 3) relative to
sal A, which is a potent and selective balanced KOR agonist
(Roth et al., 2002) (Fig. 1; Table 1). Given that RB-64 repre-
sents an extremely potent and selective G protein–biased
mouse KOR agonist with pronounced in vivo central nervous
system activity in mice (Yan et al., 2009), we elected to
compare its actions with those induced by the chemically
similar but unbiased agonist sal A and with a chemically
dissimilar unbiased agonist U69593.
In addition, we examined the effects of 200 nM U69593, sal
A, and RB-64 on KOR internalization in HEK cells. Although
U69593 and sal A induced robust internalization at 15 and 30
minutes, RB-64 induced no internalization at 15 minutes and
modest internalization at 30 minutes (Fig. 1C), consistent
with its G protein bias at this dose.
KOR-Mediated G Protein Signaling Induces Analgesia-
Like Effects. In the first set of assays, we examined the
analgesic actions of our three test KOR agonists in a hotplate
analgesic assay in bothWT and b-arrestin-2 KOmice. As can
be seen in Fig. 2A, all three compounds were analgesic in
both WT and b-arrestin-2 KO mice. Specifically, there was
an interaction of time and U69593 treatment compared with
vehicle-treated mice in WT [F(3,54) 5 11.93, P , 0.0001] and
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b-arrestin-2 KO mice [F(3,51) 5 4.25, P 5 0.0093]. WT mice
showed an analgesic effect at 10 and 20 minutes after
U69593 treatment (P , 0.001), and b-arrestin-2 KO mice
displayed an analgesic effect 10 minutes (P , 0.01) and 20
minutes (P , 0.05) after U69593 treatment (Fig. 2A). Ad-
ditionally, there was an interaction of sal A treatment and
time for both WT [F(3,63) 5 3.51, P 5 0.0201] and b-arrestin-2
KOmice [F(3,69)5 3.14, P5 0.0309]. The analgesia-like effect
of sal A occurred 10 minutes posttreatment of both WT and
b-arrestin-2 KO mice (P , 0.01) (Fig. 1B). Furthermore, there
was an interaction of time and RB-64 treatment of both WT
[F(3,57) 5 5.81, P 5 0.0016] and b-arrestin-2 KO mice [F(3,48) 5
2.96, P 5 0.0417]. The analgesia-like effects of 3 mg/kg RB-64
occurred 20 (P , 0.001, WT mice; and P , 0.01, b-arrestin-2
KO mice) and 30 minutes after treatment (P , 0.05, for both
WT and b-arrestin-2 KO mice) (Fig. 2C). There was no dif-
ference in analgesia-like responses between genotypes for
any drug conditions (Fig. 2, A–C).
To determine whether the KORmediated the analgesia-like
effects of the tested drugs, KORKO andWTmice were treated
with 1 mg/kg U69593, 3 mg/kg sal A, or 3 mg/kg RB-64, but
there was no analgesic effect in KOR KO mice compared with
Fig. 1. In vitro effects of agonists on signaling and
internalization of the mouse KOR. Dose-response
curves in HEK cells for (A) arrestin mobilization and
(B) G protein signaling–induced by U69593, sal A, and
RB-64. Error bars represent S.E.M. (C) Internaliza-
tion of mouse KOR on stimulation with agonists
(arrows indicate internalized KOR). The percent of
internalization was quantified in an unbiased manner
for the 15-minute study as previously described
(Bhatnagar et al., 2001) as follows: control = 36 6
9%; U69593 = 83 6 5% (P , 0.05 versus control);
salvinorin A = 82 6 7% (P , 0.05 versus control);
RB-64 = 32.7 6 6% (NS versus control).
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WT mice for all drug treatments [F(5,40) 5 4.734, P 5 0.0017]
(Fig. 2D). Furthermore, there was no effect of genotype on
analgesia-like effects of vehicle-treated mice [F(1,48) 5 0.37,
P 5 0.5526] (Fig. 2, A–C). However, genotype did effect
baseline performance [F(2,33) 5 3.438, P 5 0.044] (Fig. 2E).
b-Arrestin-2 KO mice have a higher baseline than WT mice
(P , 0.05), but KOR KO mice and WT mice do not differ (P .
0.05). To confirm that sal A and RB-64 have similar potencies
in vivo, we tested the analgesia-like response at a higher dose
of both sal A and RB-64 and found no significant difference
TABLE 1
Potencies and efficacies of ligands for mouse k-opioid receptor in vitro
Drug G Protein Activation Arrestin Mobilization Bias Factor
nM
Salvinorin A EC50 = 4.73 (28.33 6 0.04) EC50 = 10.5 (27.98 6 0.05) 1
Emax = 101 Emax = 93.6
U69593 EC50 = 3.68 (28.43 6 0.04) EC50 = 25.4 (27.59 6 0.03) 3 G protein
Emax = 99.7 Emax = 100
RB-64 EC50 = 5.22 (27.92 6 0.05) EC50 = 1130 (25.94 6 0.03) 96 G protein
Emax = 99.0 Emax = 126
Fig. 2. KOR agonist–induced G protein signaling causes analgesia-like effects in the hotplate assay. (A) U69593 caused an analgesia-like effect in WT
(n = 8) and b-arrestin-2 KOmice (n = 10) 10 and 20 minutes after treatment. (B) Sal A produced analgesia-like effects in WTmice (n = 11) and b-arrestin-2
KO mice (n = 16) 10 minutes after treatment. (C) RB-64 induced analgesia-like effects in WT (n = 9) and b-arrestin-2 KO mice (n = 9) 20 and 30 minutes
after treatment. The vehicle-treated WTmice (n = 12) and b-arrestin-2 KO mice (n = 9) showed no differences in response. (D) U69593, sal A, and RB-64
showed a KOR-selective effect when comparing KOR KOmice (n = 8 for all drug treatments) andWTmice (n = 9, 7, and 6, for U69593, sal A, and RB-64).
Mice were tested 20 minutes after treatment of U69593 and sal A and 10 minutes after treatment with sal A. (E) There was an increased baseline
performance in the hotplate assay for b-arrestin-2 KO mice compared with WT mice, but no difference was seen in baseline between KOR KO and WT
mice (n = 12 for all genotypes). (F) A higher dose of RB-64 (n = 10) or sal A (n = 9) does not increase the analgesic response in WT mice. Data are plotted
as the percent of baseline latency to respond for each animal, and baseline was established on the day of testing before drug treatment 6 S.E.M. (A–D)
*P , 0.05; **P , 0.01; ***P , 0.001. BArr2, b-arrestin-2.
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among the 3 mg/kg dose versus the 10 mg/kg dose for either
drug (P . 0.05) (Fig. 2F).
The G Protein–Biased KOR Agonist Induces Aver-
sion in a Conditioned Place Aversion Assay. We next
tested all three KOR agonists in a commonly used assay of
aversion—namely, the conditioned place aversion assay. As
can be seen all three KOR agonists cause an aversion-like
response that can be observed in both WT and b-arrestin-2
KO mice (F(11,78) 5 3.241, P 5 0.0011) (Fig. 3A). In WT mice,
there was an aversive effect of 1 mg/kg U69593 (P , 0.05),
3 mg/kg sal A (P, 0.01), and 3 mg/kg RB-64 (P, 0.05), but no
aversive effect of the lower tested doses of sal A (1 mg/kg; P .
0.05) or RB-64 (1 mg/kg; P . 0.05). Similarly, deleting
b-arrestin-2 did not significantly alter the aversion-like action
of 1 mg/kg U69593 (P , 0.05), 3 mg/kg sal A (P , 0.05), or
3 mg/kg RB-64 (P, 0.05). Similarly, there was no aversion-like
action of the lower tested dose of sal A (1 mg/kg; P . 0.05)
or RB-64 (1 mg/kg; P . 0.05). Furthermore, there was no
difference in aversion-like effects between WT and b-arrestin
2 KO mice for any of the treatment conditions (vehicle, 1 mg/kg
U69593, 1 mg/kg sal A, 3 mg/kg sal A, 1 mg/kg RB-64, or
3 mg/kg RB-64) (P . 0.05, for all conditions).
Because we used a vehicle (10% Tween-80) that could alter
the aversive response to the test agents, we also examined the
effect of 1 mg/kg U69593 or 3 mg/kg RB-64 dissolved in
dimethylsulfoxide instead of 10% Tween-80. For these
studies, the test drugs were microinjected into WT mice using
a Hamilton syringe (Hamilton, Reno, NV) in a total volume of
1 ml for each milligram of mouse weight. Using this alter-
native vehicle, we again observed no significant difference
in aversion-like actions of U69593 and RB-64 [t(10) 5 1.237,
P . 0.2442] (Fig. 3B).
The G Protein–Biased Agonist RB-64 Does Not
Impair Rotarod Performance. The effect of opioids on
rotarod performance has long been used to evaluate potential
sedative or coordination-impairing actions of KOR agonists
(Kieffer, 1999). Here we found that the tested unbiased KOR
agonists caused a strong deficit in rotarod performance and
that this effect was greater in WT mice than in b-arrestin-2
KO mice (Fig. 4). There was a greater performance deficit in
Fig. 3. KOR agonist–induced G protein signaling causes
conditioned place aversion. (A) U69593 (1 mg/kg)-induced
aversion inWT (n = 8) andb-arrestin-2KOmice (n = 7).
1 mg/kg sal A had no effect onWT (n = 6) or b-arrestin-
2 KOmice (n = 8), but 3 mg/kg sal A did cause aversion
in WT (n = 9) and b-arrestin-2 KO mice (n = 6). RB-64
(1 mg/kg) did not cause aversion in WT (n = 8) or
b-arrestin-2 KO mice (n = 7), but 3 mg/kg RB-64 did
induce aversion in bothWT (n = 8) and b-arrestin-2 KO
mice (n = 7). All P values were generated in comparison
with vehicle-treatedWT (n = 8) orb-arrestin-2 KOmice
(n = 8). (B) Using a dimethylsulfoxide (DMSO) vehicle
instead of 10% Tween-80 did not cause an increased
aversion in U69593-treated mice (n = 6) relative to
RB-64 (n = 6). This was done to determine whether 10%
Tween-80 causes a ceiling effect in U69593 mice. Using
either vehicle (DMSO or 10%Tween-80), no difference is
seen in the aversion induced by U69593 and 3 mg/kg
RB64. Data are plotted as amount of time spent in drug-
paired room during after the test compared with
pretest. Data are plotted as amount of time spent in
drug-paired room during posttest compared with
pretest 6 S.E.M. *P , 0.05; **P , 0.01. BArr2,
b-arrestin-2.
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WT mice than b-arrestin-2 KO mice for both 1 mg/kg U69593
treatment [F(1,88)515.38, P , 0.003] and 3 mg/kg sal A treat-
ment [F(1,96)5 13.69,P, 0.0006] (Fig. 4, A andB). Significantly,
3 mg/kg RB-64 had no effect on rotarod performance in either
genotype [F(1,24)50.14, P 5 0.7124] (Fig. 4C).
We also examined the effect of higher doses of U69593, sal
A, and RB-64 on rotarod performance in WT and b-arrestin-2
KOmice. No difference was seen in the performance of theWT
and b-arrestin-2 KO mice treated with 3 mg/kg U69593
[F(1,66) 5 0.26, P 5 0.615] (Fig. 4D); however, in both genotypes,
a strong deficit in performance was observed. We found that
10 mg/kg sal A induced a larger deficit in performance in WT
mice than b-arrestin-2 KO mice [F(1,34) 5 11.65, P 5 0.0033]
(Fig. 4E). Furthermore, 10 mg/kg RB-64 induced no effect on
rotarod performance in either genotype [F(1,32) 5 0.05,
P 5 0.8288] (Fig. 4F).
To ensure that the effect of these drugs was due to the KOR,
we tested them in KOR KO mice and found that KOR KO
animals show no deficit in rotarod performance when treated
with 1 mg/kg U69593 or 3 mg/kg sal A (Fig. 4G). For both
drug treatments, all KOR KO animals performed at 100%
baseline for all time points tested. Additionally, there was
no difference in baseline performance among genotypes
[F(2,53) 5 0.6736, P 5 0.5142] (Fig. 4H).
The G Protein–Biased KOR Agonist RB-64 Does Not
Affect Novelty-Induced Locomotion. The KOR agonists
are also well known to induce sedation and to decrease
novelty-induced locomotion (Kieffer, 1999). We therefore next
Fig. 4. b-arrestin 2 signaling contributes to KOR agonist–induced rotarod deficit. (A) U69593 induced a rotarod deficit in both WT (n = 23) b-arrestin-2
KO mice (n = 23) but produced a larger deficit in performance for WT mice compared with b-arrestin-2 KO mice (P , 0.0003). (B) Sal A also produced
a larger deficit in rotarod performance in WT mice (n = 25) than in b-arrestin-2 KO mice (n = 25) (P , 0.0006). (C) RB-64 (3 mg/kg) had no effect on
performance in either WT (n = 5) or b-arrestin-2 KO mice (n = 5). (D) 3 mg/kg U69593 had a strong effect in both WT (n = 18) and b-arrestin-2 KO mice
(n = 17). (E) sal A (10 mg/kg) produced a larger deficit in rotarod performance in WT mice (n = 10) than in b-arrestin-2 KO mice (n = 10). (F) Ten
milligrams per kilogram RB-64 had no effect on either WT (n = 8) or b-arrestin-2 KO mice (n = 10). (G) U69593 (n = 5) and sal A (n = 5) had no effect on
rotarod performance in KORKOmice. (H) No difference was seen in rotarod baseline performances between genotypes. Data are plotted as the percent of
baseline performance (A–G) or time spent on rod (H) 6 S.E.M. BArr2, b-arrestin-2.
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evaluated our three KOR agonists in a novelty-induced
locomotion paradigm as described previously (Allen et al.,
2011; Besnard et al., 2012) (Fig. 5). Here we pooled the data
for the first 30 minutes of each treatment condition to
compare the effects of all treatments and genotypes on total
distance traveled (Fig. 5) and found that the treatments had
different effects on locomotion [F(7,49)521.97, P , 0.0001]. In
both WT and b-arrestin-2 KO mice, 1 mg/kg U69593 caused
a large decrease in distance traveled (P , 0.001, for both WT
and b-arrestin-2 KO mice), and 3 mg/kg sal A similarly
decreased distance traveled (P , 0.001, for both WT and
b-arrestin-2 KO mice), but there was no effect of 3 mg/kg RB-
64 on distance traveled (P. 0.05, for both WT and b-arrestin-
2 KO mice). Additionally, there was no difference in distance
traveled between WT and b-arrestin-2 KO mice for any
treatment condition.
A G Protein–Biased KOR Agonist Does Not Display
Anhedonia-Like Effects. The KOR agonists are well
known to induce dysphoria and an anhedonic-like response
in humans and mice (Potter et al., 2011; Ranganathan et al.,
2012). For these studies, the anhedonia-like effects of sal A,
RB-64, or U69593 were tested in C57BL/6J mice using the
curve-shift method of ICSS (Carlezon and Chartoff, 2007).
The mice responded in a frequency-dependent manner for
BSR, as shown by the average baseline rate-frequency curves
(Fig. 6A). There was an interaction between frequency and
drug treatment [F(42,672) 5 12.98, P , 0.0001]; all three drugs
caused a rightward shift in average rate-frequency curves at
a dose of 1 mg/kg where U69593 is the most potent, followed
by sal A and RB-64 (Fig. 6A).
After a daily baseline measurement, the effects of each drug
(0.01–1.0 mg/kg) on the minimum frequency that maintained
responding (BSR threshold; Fig. 6B), and maximum operant
response rate (MAX; Fig. 6C) during four 15-minute response
periods post-treatment were measured (Fig. 6). A significant
interaction was revealed between drug and dose on BSR
threshold during the first posttreatment period [F(8,96)5 2.439,
P5 0.019], the second post-treatment period [F(8.96) 5 8.776,
Fig. 5. Effect of KOR agonists on novelty induced locomotion. (A) The novelty induced locomotion for vehicle-treated WT (n = 7) and b-arrestin-2 KO
mice (n = 8). Both genotypes habituated and decreased activity after approximately 30 minutes. (B) U69593 did not differentially affect WT (n = 6) and
b-arrestin-2 KOmice (n = 8). (C) No difference was seen in locomotion for sal A treatment betweenWT (n = 6) and b-arrestin-2 KOmice (n = 6). (D) RB-64
induced similar effects in both WT (n = 6) and b-arrestin-2 KO mice (n = 7). (E) The total distance traveled in the first 30 minutes (time before
habituation). U69593 and sal A caused a strong decrease in activity, whereas RB-64 had no effect relative to vehicle-treated mice. Variance is
represented as S.E.M. ***P , 0.001. BArr2, b-arrestin-2.
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P , 0.001], the third post-treatment period [F(8,96) 5 6.111,
P , 0.0001], and the fourth post-treatment period [F(8,96) 5
2.499, P 5 0.016]. For the first post-treatment period, 1 mg/kg
sal A and U69593 elevated BSR threshold compared with
vehicle (P , 0.001 for both). For the second post-treatment
period, 0.3 U69593, 1.0 mg/kg U69593, and 1.0 mg/kg sal A
elevated BSR threshold compared with vehicle (P, 0.001 for
each). There was a differential effect of treatment at 1.0 mg/kg
dose: U69593 versus RB-64 (P , 0.001), U69593 versus
sal A (P 5 0.016), and sal A versus RB-64 (P , 0.001). During
the third and fourth post-treatment periods, 1.0 mg/kg
U69593 significantly elevated BSR thresholds compared with
vehicle (P , 0.001). Additionally, U69593 differed from sal A
and RB64 during the third (P , 0.001) and fourth post-
treatment periods (P 5 0.005 and P 5 0.01 for sal A and RB-
64, respectively). All doses of RB-64 had no significant effect
on BSR (Fig. 6B).
A significant interaction between drug and dose on MAX
was revealed at the second post-treatment period [F(8,96) 5
14.317, P , 0.001], the third post-treatment period [F(8,96) 5
18.426, P , 0.001], and the fourth post-treatment period
[F(8,96) 5 7.896, P , 0.001]. During the second post-treatment
Fig. 6. A G protein–biased KOR agonist does not display anhedonia-like effects. (A) The response for different frequencies of brain stimulation reward
by C57BL/6J mice treated with 1 mg/kg drug. All treatments showed a rightward shift in the average rate-frequency curves compared with vehicle;
U69593 had the largest effect, followed by sal A, and then RB-64 (n = 13 for all conditions). (B) Dose-response relationship for the effects of U69593, sal A,
and RB-64 on the BSR. Results are presented as mean percentages of preinjection baseline during the four 15-minute postinjection response series 6
S.E.M. *Significance (P , 0.05) of drug versus vehicle. #Significance (P , 0.05) of drug compared with another drug treatment. (C) Dose-response
relationship for the effects of U69593, sal A, and RB-64 on the maximum response rate (MAX) in C57BL/6J mice. Results are presented as mean
percentage of preinjection baseline during the four 15-minute postinjection response periods 6 S.E.M. *Significance (P , 0.05) versus vehicle.
#Significance (P , 0.05) versus a separate drug treatment. n = 13 for all treatment conditions.
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period, 0.3 mg/kg U69593, 1.0 mg/kg U69593, or 1.0 mg/kg sal
A significantly decreased MAX compared with vehicle (P 5
0.001 for each). Furthermore, the drugs caused differential
effects at the 0.3 mg/kg dose between U69593 and sal A (P ,
0.001), and U69593 and RB-64 (P , 0.001), but not sal A and
RB-64. Additionally, the drugs had differential effects at a
1 mg/kg dose between all pairs of drugs: U69593 and sal A
(P, 0.001), U69593 andRB-64 (P, 0.001), and sal A andRB-64
(P 5 0.027). During the third post-treatment period, only
U69593 (both 0.3 and 1 mg/kg) decreased MAX compared
with vehicle, sal A, and RB-64 (P , 0.001 for each). During the
fourth post-treatment period, only 1.0mg/kgU69593 decreased
MAX compared with vehicle, sal A, and RB-64 (P , 0.001 for
each) (Fig. 6C).
Discussion
The major finding of this study is that the selective G
protein–biased KOR agonist RB-64 is analgesic with fewer of
the prototypical side effects associated with unbiased KOR
agonists. Prototypical KOR agonists are well known to be
effective analgesics with low dependence and abuse potential
(Tao et al., 2008; Wee and Koob, 2010; Prevatt-Smith et al.,
2011). Unfortunately, KOR agonists can cause dysphoria,
psychotomimesis, hallucinations, and anhedonia-like effects
(Pfeiffer et al., 1986; Ebner et al., 2010; Potter et al., 2011;
Ranganathan et al., 2012). Our findings are consistent with
the hypothesis that creating G protein–biased KOR agonists
represents a novel approach for creating analgesics with
fewer side effects.
Elegant prior studies have provided evidence that KOR-
mediated p38 MAPK signaling regulates dysphoria and that
G protein signaling regulates analgesia (Bruchas et al., 2007).
Before the current study, the role of b-arrestin-2 signaling for
the actions of KOR agonists has not been directly tested in
vivo. To investigate further which KOR signaling pathways
contribute to specific behaviors, we examined WT and
b-arrestin-2 KO mice in a number of behavioral paradigms
with a G protein–biased ligand (RB-64) and two unbiased
ligands (U69593 and sal A). If an expected KOR-induced
response is absent in b-arrestin-2 KO mice, b-arrestin-2
signaling may be involved in mediating that response.
Additionally, if RB-64 fails to induce a response similar to
the unbiased ligands U69593 and sal A, that would suggest
that RB-64 has a biased signaling profile in vivo.
We previously showed that RB-64 is a G protein–biased,
human KOR ligand using in vitro signaling assay, and here
we show a similar effect in activation of the mouse KOR (Fig. 1;
Table 1). Additionally, we observed an altered KOR internal-
ization on RB-64 stimulation relative to the unbiased KOR
ligands U69593 and sal A (Fig. 1C). In the future, an in-depth
investigation of downstream signaling events activated by
a diverse set of biased and unbiased ligands will provide major
insights into what contributes to behavior beyond G proteins,
arrestin, and p38 MAPK.
The analgesia-like effects of U69593 and sal A shown
here are similar to those of previous reports (Waddell and
Holtzman, 1999; Ansonoff et al., 2006). This study shows no
statistical difference in analgesia-like responses between WT
and b-arrestin-2 KO mice treated with KOR agonists (Fig. 2,
A–C). However, we did observe a significant difference in
baseline analgesia between WT and b-arrestin-2 KO mice,
consistent with previous reports (Fig. 2E) (Bohn et al., 2002).
Additionally, the G protein–biased ligand (RB-64) showed
a significant and long-lasting analgesia-like effect (Fig. 2C).
This long-lasting effect may be due to the lack of b-arrestin-2
recruitment, and therefore altered receptor desensitization,
but it could also be due to differential pharmacokinetics of the
test agents. The transient effect of sal A was expected because
it is known that sal A has a very short half-life in vivo owing to
plasma esterase activity (Cunningham et al., 2011). Impor-
tantly, the analgesia-like effect of U69593, sal A, and RB-64
was shown to be specific to KOR and not due to an off-target
effect because there was no analgesic response in KOR KO
mice treated with U69593, sal A, or RB-64 (Fig. 2D). These
studies suggest that G protein–signaling mediates KOR-
induced analgesia-like effects. The analgesic studies are
consistent with recent hints that a G protein–biased KOR
agonist of a different chemotype can induce analgesia-like
effects (Zhou et al., 2013).
To determine whether b-arrestin-2 signaling mediates
KOR-mediated aversion, as previously hypothesized (Bruchas
and Chavkin, 2010), we examined the effects of U69593, sal A,
and RB-64 in both WT and b-arrestin-2 KO mice in the
conditioned place aversion behavioral paradigm. U69593 and
sal A have previously been shown to induce aversion in this
paradigm (Shippenberg and Herz, 1986; McLaughlin et al.,
2003; Zhang et al., 2005; Tejeda et al., 2013; Sufka et al.,
2014). We found that U69593, sal A, and RB-64 all caused
a similar degree of aversion-like activity in both WT and
b-arrestin-2 KO mice (Fig. 3A). This finding suggests that G
protein signaling, not b-arrestin-2 signaling, mediates the
aversion-like effect measured in this assay. It is important to
note that CPA is a measure of conditioned learning, and the
avoidance observed in this assay could be caused by actions
of the drugs not directly associated with an aversive sensa-
tion. Additionally, previous reports link the activation of p38
MAPK to KOR-induced aversion that was hypothesized to be
mediated by b-arrestin-2. Our results suggest that b-arrestin-2
is not the only factor involved in mediated KOR dependent
aversion. Here p38 MAPK may be activated by an alterna-
tive signaling node or the aversion may be induced by a p38
MAPK-independentmanner. Further investigation of the global
signaling events activated by KOR biased and unbiased ligands
will be illuminating.
To explore further the specific KOR-mediated signaling
cascades that mediate its actions on reward and various
hedonic states, we performed ICSS experiments to determine
the effect of G protein–biased ligands on motivation and brain
reward circuitry. Previous reports have shown a negative
effect of KOR agonists on BSR, implying that treatment with
KOR agonists reduces the hedonic value of brain stimulation
reward (Ebner et al., 2010; Negus et al., 2010). Because RB-64
appears biased in vivo, we treated WT mice with U69593, sal
A, or RB-64. Interestingly, U69593 and sal A reduce an
animal’s motivation to work for brain stimulation reward,
whereas RB-64 lacks this effect (Fig. 6). These data are
consistent with the original premise that b-arrestin-2 may
mediate some of the negative side effects of KOR agonism;
however, it is now clear that other signaling components may
also mediate KOR-induced negative side effects.
To explore further how G protein and b-arrestin-2 signaling
contribute to KOR-mediated behavioral effects, we measured
the performance of WT and b-arrestin-2 KO mice in the
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rotarod assay after treatment with U69593, sal A, and RB-64.
This assay measures balance and motor coordination and has
long been used to assess the potential liability of central
nervous system–active drugs. Both 1mg/kgU69593 and 3mg/kg
sal A caused a stronger deficit in rotarod performance in WT
mice than in b-arrestin-2 KO mice, whereas 3 mg/kg RB-64
had absolutely no effect on performance in either genotype
(Fig. 4, A–C). Additionally, we found that at a higher dose of
3 mg/kg U69593, the deficit in rotarod performance is strong in
both genotypes (Fig. 4D). At all doses of sal A tested, there was
a significant difference in performance between genotypes
(Fig. 4E), but we expect that at higher doses, both genotypes
would perform equally poorly as seen with 3 mg/kg U69593.
Interestingly, even with a dose of 10 mg/kg RB-64, we ob-
served little effect on rotarod performance and no difference
between genotypes (Fig. 4F). These findings suggest that
b-arrestin-2 signaling is important for the KOR-induced deficit
in rotarod performance. Furthermore, the complete lack of an
effect of RB-64 on rotarod performance suggests that there
could be some b-arrestin-1 compensation in the b-arrestin-2
KO mice, leading to the slight performance deficit observed
when mice were treated with U69593 and sal A. KOR KOmice
were treated with U69593 and sal A and showed no impair-
ment in performance, suggesting that the effects of U69593
and sal A are mediated through the KOR. Taken together,
these data suggest that b-arrestin-2 signaling contributes to
KOR-induced rotarod deficit and strongly suggest that RB-64
is an extremely G protein–biased ligand in vivo.
The effect of these drugs on the rotarod assay could be due
to a number of factors: sedation, altered motor coordination,
and/or a cognitive disruption. To understand more clearly
why RB-64 does not affect rotarod performance but U69593
and sal A cause an impairment in performance, we tested the
locomotor-attenuating actions of these drugs in the novelty-
induced locomotion assay. We observed decreased locomotion
in both WT and b-arrestin-2 KO mice treated with U69593 or
sal A, but not RB-64 (Fig. 5). Although bothWTand b-arrestin-2
KO mice showed a strong suppression of locomotion, the
G-protein–biased ligand did not cause this effect. It is possible
that, in this behavioral paradigm, there is compensation for
the absence of b-arrestin-2 by b-arrestin-1.
Despite a lack of effect of RB-64 on novelty-induced
locomotion, the rotarod assay, and MAX and BSR thresholds,
we conclude that RB-64 is active in the brain because of the
strong effects observed in the hotplate and CPA paradigms.
Further support comes from our prior studies showing that
RB-64 has potent effects on prepulse inhibition (Yan et al.,
2009). We attempted to quantify RB-64 levels in the brain
using light chromatography–tandem mass spectrometry;
however, the collection conditions used for this analysis
interfered with the detection of RB-64. A more thorough
investigation with additional G protein–biased, b-arrestin
biased and, perhaps, p38 MAPK biased KOR selective ligands
paired with a full pharmacokinetic evaluation will clarify the
role of specific signaling cascades in KOR-dependent behav-
iors. Furthermore, RB-64 was originally synthesized to
covalently bind KORs (Yan et al., 2009) and in preliminary
studies (F. Yan and B. L. Roth, unpublished observations), we
found that RB-64, when administered in vivo, apparently does
not irreversibly interact with KOR.
In summary, our findings suggest that KOR-mediated G
protein signaling induces analgesia-like effects and aversion-
like actions in theCPAassay,whereasKOR-mediatedb-arrestin-2
signaling mediates motor incoordination. Given the lack of
effect of the G protein–biased ligand RB-64 on sedation and
anhedonia, our data are consistent with the hypothesis that
b-arrestin-2 activity is essential for the sedative and anhedonia-
like actions of KOR agonists. Based on these results, our
studies imply that G protein–biased KOR agonists may rep-
resent novel analgesics with fewer side effects compared with
unbiased agonists.
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